

1. Alexander KP, Chen AY, Roe MT, et al for the CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA* 2005;294:3108-3116.
2. Allen KB, Dowling D, Fudge TL, Schoettle GP, Selinger SL, Gangahar M, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. *N Eng J Med* 1999; 341:1029-36.
3. Ancillo P, Civeira E, Ferrero J, Hernando G, Jiménez MJ, Piqué M, et al. Angina inestable en la unidad de cuidados intensivos. *Med Intensiva* 2000;24 (Suppl1):11-27.
4. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision-making. *JAMA* 2000;284(7):835-42. Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. *International Cardiology Forum. Am Heart J* 2000; 139(3):461-75.
5. Antman EM. "I can see clearly now": a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes. *Eur Heart J* 2002; 23: 1408-11.
6. Antoniucci D. Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients. *Eur Heart J Suppl* 2007; 9: A32-A36.
7. Arboleda JA, Marfil JL, Pérez-Montaut I, Siendones R, Torres F, Benito J, et al. *Guía Clínica del Plan de Atención Extrahospitalaria al Síndrome Coronario Agudo*. Barcelona: Serper; 2001.
8. Balady GJ, Ades PA, Comoss P, Limacher M, Pina IL, Southard D, et al. Core Components of Cardiac Rehabilitation/Secondary Prevention Programs. A Statement for Healthcare Professionals From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. *Circulation* 2000; 102:1069-73.
9. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. *J Am Coll Cardiol* 2006 ;48:1319-1325
10. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent STsegment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. *Eur Heart J* 2002; 23:1809-1840.

11. Blazing MA, de Lemos JA, White HD, et al.. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. *JAMA* 2004; 292:55-64.
12. Boden WE, McKay RG. Optimal treatment of acute coronary syndromes-An evolving strategy. *N Engl J Med* 2001; 344:1939-42.
13. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F y cols. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *Lancet* 2002; 359: 189-98.
14. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization and unstable angina and non-ST-segment elevation myocardial infarction (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2001. Oxford: Update Software.
15. Braunwald E, Antman EM, Beasley JW, Calif RM, Cheitlin MD, Hochmen JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-74.
16. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. *Circulation* 2002; 106:1622-6.
17. Bueno H, Bardají A, Fernández-Ortiz A, Marrugat J, Martí H y Heras M. Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal Español). *Rev Esp Cardiol* 2005; 58: 244 - 252
18. Calderón E, Cotos R, Marín I, Briones E, Pérez B, Grilo A. Mapa de evidencias para el tratamiento de la angina inestable en la cabecera del paciente. Etapa preliminar para el desarrollo de una Guía de Práctica Clínica. *Med Clin* 2000; 114(Supl 2):19-23.
19. Calvin JE, Klein LW, VandenBerg EJ, Meyer P, Parrillo JE. Modelo validado para la estratificación de riesgo con predicción certera de bajo riesgo en pacientes con angina inestable. *JACC (ed. Esp.)* 2001;10(2):73-79.
20. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-1504.
21. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor Tirofiban. *N Engl J Med* 2001; 344:1879-87.
22. Cannon CP. Evidence-based risk stratification to target therapies in acute coronary syndromes. *Circulation* 2002; 106:1588-91.

23. Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267-78.
24. Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected acute myocardial infarction or unstable angina. American College of Emergency Physicians. *Ann Emerg Med* 2000;35:521-5.
25. Cohen M, Theroux P, Borzak S, Frey MJ, White HD, Van Mieghem W et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin. *Am Heart J* 2002; 144: 470-7.
26. Collet JP, Dumaine R, Montalescot G. Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. *Eur Heart J Suppl* 2007; 9: A11-A24.
27. Cook JJ, Bednar B, Lynch JJ, Gould RJ, Egbertson MS, Halczenko W, et al. Tirofiban (Agrastat à). *Cardiovascular Drug Reviews* 1999; 17:199-224.
28. De la Torre JM, Fernández M, Royuela N, Gómez I, Enríquez SG, Zueco J, et al. Angina inestable en el paciente octogenario: ¿es factible y eficaz el abordaje invasivo? *Rev Esp Cardiol* 2001; 54:679-684.
29. De Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. *Eur Heart J* 2004;25:1688-1694.
30. De Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. *N Engl J Med* 2005;353:1095-1104
31. Dudek D, Dziewierz A, Chyrchel B, Polonski L, Legutko J, Dubiel JS. Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight). *Eur Heart J Suppl* 2007; 9: A25-A31.
32. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, et al. ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations. A Report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). *Circulation* 1999; 100 :1464- 80.
33. Farkouh ME, Smars PA, Reeder GS, Zinsmeister AR, Evans RW, Meloy TD, et al. A clinical trial of a chest-pain observation unit for patients with unstable angina. *N Eng J Med* 1998; 339:1882-8.
34. Ferguson JJ, Califf RM, Antman EM, et al.. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;292:45-54.

35. Figueras J, Monasterio Y, Lindón RM, Nieto E, Soler-Soler J. Producción de trombina y actividad fibrinolítica en pacientes con infarto agudo de miocardio o angina inestable: evolución intrahospitalaria y relación con la aparición de angina recidivante en reposo. *JACC* 2001;10 (2):61-69.
36. Gabe ED, Favalaro RR, Favalaro MR, Raffaelli HA, Machain AH, Abud JA, et al. Cirugía coronaria en pacientes ancianos. Resultados hospitalarios y a largo plazo. *Rev Esp Cardiol* 2001; 54:709-714.
37. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation* 2004; 110: 227-239.
38. Grupo del Estudio CAMBIE ed. Guía de Práctica Clínica basada en la evidencia sobre el manejo de la angina inestable. Sevilla: Agencia de Evaluación de Tecnología Sanitarias de Andalucía, 1998.GRAFÍA
39. Hamm CW, Braunwald E. A Classification of Unstable Angina Revisited. *Circulation* 2000;102:118-22.
40. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac Troponin T or Troponin I. *N Eng J Med* 1997; 337:1648-53.
41. Heras M, Fernández A, Gómez A, Iriarte, JA, Lindón RM, Pérez F, Roldan I. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. *Rev Esp Cardiol* 1999; 52:801-20.
42. Jurlander B, Farhi ER, Banas JJ Jr, Keany CM, Balu D, Grande P, et al. Coronary angiographic findings and troponin T in patients with unstable angina pectoris. *Am J Cardiol* 2000; 85(7): 810-4.
43. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. *JAMA* 2006;295:1531-1538
44. Katz DA, Griffith JL, Beshansky JR, Selker HP. The use of empiric clinical data in the evaluation of practice guidelines for unstable angina. *JAMA* 1996;276 (19):961-2.
45. Katz DA. Barriers between guidelines and improved patient care: an analysis of AHCPR's Unstable Angina Clinical Practice Guideline. Agency for Health Care Policy and Research. Health Serv Res 1999.
46. Kereiakes DJ, Broderick TM, Roth EM, Whang D, ShimshaK, Runyon JP, et al. Time Course, Magnitude and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention. *Am J Cardiol* 1999; 84:391-5.

47. Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. *Am Heart J* 2002;144:615-624.
48. Klootwijk P, Hamm C. Acute coronary syndromes: Diagnosis. *Lancet* 1999;353 (suppl II):10-15.
49. Lee TH. Guidelines: Management of Unstable Angina/Non-ST Segment Elevation Myocardial Infarction. En: Braunwald E, editor: *Heart Disease*. 6ª ed. Philadelphia: Saunders; 2001:1264-71.
50. Lopez Bescós L, Aros F, Lidón RM, Cequier A, Bueno H, Alonso JJ y cols. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. *Rev Esp Cardiol* 2002; 55:631-42.
51. López L, Fernández A, Bueno H, Coma I, Lindón RM, Cequier A, et al. Guías de Práctica Clínica (GPC) de la Sociedad Española de Cardiología (SEC) en Angina Inestable. En: Marín E, Rodríguez L, Bosch J, Iñiguez A, editores. GPC de la SEC. Madrid: SEC; 2000. p.53-82.
52. López-Sedón J, López E. Nuevos criterios de diagnóstico de infarto de miocardio: orden en el caos. *Rev Esp Cardiol* 2001;42:669-674.
53. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH et al. Cost and cost-effectiveness of an early invasive vs. conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. *JAMA* 2002; 288:1851-8.
54. McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. *Health Technol Assess* 2000; 4(30).
55. Medicare Services Advisory Committee. Final assessment report on Transmyocardial Laser Revascularisation. Commonwealth Ministry for Health and Aged Care 1999. Available from: <http://www.health.gov.au/haf/masc>. Accessed on 14/02/2001.
56. Mehta SR, Cannon CP, Fox KA, et al. Routine versus selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of randomized trials. *JAMA* 2005; 293:2908-2917.
57. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, y cols, for the Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001; 358:527-33.
58. Meuwissen M, Piek JJ, Van der Wal AC, Chamuleau SA; Koch KT, Teeling P, et al. Recurrent unstable angina after directional coronary atherectomy is related to the extent of initial coronary plaque inflammation. *J Am Coll Cardiol* 2001;37:1271-6.

59. Mishra B, Jackson G. Unstable angina: A review and practical guide to management. *Int J Clin Pract* 1999; 53 (7):530-534.
60. National Institute for Clinical Excellence. Guidance of the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. Technology appraisal guidance N° 47. September 2002.
61. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: A randomized controlled trial. *JAMA* 2003 ;290:1593-1599.
62. Neumann FJ, Kastrati A, Schwarzer G. New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective. *Eur Heart J Suppl* 2007; 9: A4-A10.
63. NHS Development and Evaluation Committee on Dalteparin and enoxaparin for unstable angina and non-Q-wave myocardial infarction: update. 2000 Mar; 108. Available from: <http://www.epi.bris.ac.uk/rd> or <http://www.hta.nhsweb.nhs.uk/rapidh/>.
64. NHS Development and Evaluation Committee on Exercise testing following unstable coronary artery disease or myocardial infarction. 1998 Dec; 92. Available from: <http://www.epi.bris.ac.uk/rd> or <http://www.hta.nhsweb.nhs.uk/rapidh/>.
65. O'shea JC, Madan M, Cantor WJ, Pacchiana CM, Greenberg S, Joseph DM, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatid in percutaneous coronary intervention. *Am Heart J* 2000; 140:834-9.
66. Petersen JL, Mahaffey KW, Hasselblad V, et al.. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. *JAMA* 2004; 292:89-96.
67. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. *JAMA* 2006; 295:1912-1920.
68. Piek JJ, Meuwissen M, Van der Wal AC, Chamuleau SA; Koch KT, Teeling P, et al. Plaque inflammation in restenotic coronary lesions of patients with stable or unstable angina. *J Am Coll Cardiol* 2000; 35(4): 963-7.
69. Roffi M, Chef DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. *Eur Heart J* 2002; 23:1441-48.
70. Richard A, Bossaert L, Filippatos GS. European Resuscitation Council guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes. *Resuscitation* (2005) 67S1,S87-S96.
71. Schwartz GC, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters A, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001; 285:1758-60.

72. Sitges M, Bosch X, Sanz G. Eficacia de los bloqueadores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos. *Rev Esp Cardiol* 2000; 53:422-39.
73. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of 1993 PTCA Guidelines)-Executive Summary. A Report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). *JACC* 2001; 37: 2215-38.
74. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med* 2006; 355:2203-2216.
75. Strategies for optimizing outcomes in the NSTEMI-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report. *J Invasive Cardiol* 2006;18:617-39.
76. The Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of Clopidogrel in addition to Aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001; 345:494-502.
77. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non- Q-wave myocardial infarction. *N Eng J Med* 1998; 338:1488-97.
78. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with Eptifibatid in patients with acute coronary syndromes. *N Eng J Med* 1998; 339:436-43.
79. Throckmorton DC. Future trials of antiplatelet agents in cardiac ischemia. *N Engl J Med* 2001; 344:1937-8.
80. Topol EJ, Moliterno DJ, Herrmann HC, Power ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIa/IIIa inhibitors, Tirofiban and Abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. *N Engl J Med* 2001; 344:1888-94.
81. Villar F et al. Documento de consenso. Recomendaciones para el control de la colesterolemia en España. *Clin Invest Arteriosclerosis* 2000;12 (6).
82. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med* 2006; 354:1464-1476.

## **BIBLIOGRAFÍA CONSULTADA EN EL SUBPROCESO: CUIDADOS DE ENFERMERÍA EN PACIENTES CON DOLOR TORÁCICO POTENCIALMENTE GRAVE (además de la referida en el Proceso de Dolor Torácico no filiado)**

1. Aldasoro, Elena; Calvo, Montse; Esnaola, Santiago; Hurtado de Saracho, Iraida; Alonso, Eva; Audicana, Covadonga; Arós, Fernando; Lekuona, Iñaki; Arteagoitia, José M; Basterretxea, Mikel; Marrugat, Jaime. Diferencias de género en el tratamiento de revascularización precoz del infarto agudo de miocardio. *Med Clínica* 2007;128:81-85.
2. Ariza Olarte, Claudia. Atención de enfermería al paciente con infarto agudo de miocardio en la fase aguda. *Rev Enferm Cardiol* 2001;8:33-40.
3. Azaldegui Berroeta, F. Manejo extrahospitalario del dolor torácico no traumático. *Sal Rural* 2004;21:17-38.
4. García Mora, Sandra Isabel. Enfermería ante el dolor torácico de origen cardiológico en una unidad de hospitalización. *Rev Enferm Cardiol* 2005;12:45-49.
5. Goldich, Guy. Infarto de miocardio: los nuevos protocolos *Nursing* 2006;9:30-33.
6. Gregoire J. Evaluating thoracic pain in triage. *Perspect Infirm.* 2006; 3:33-6.
7. Jenifer M; Miracle V. Utilización del ECG para detectar el infarto de miocardio. *Nursing* 2000;18(1):17-22.
8. López de la Iglesia, J; Martínez Ramos, E; Pardo Franco, L; Escudero Álvarez, S; Cañón de la Parra, Rl; Costas Mira, MT. Encuesta a los pacientes con cardiopatía isquémica sobre el modo de actuación ante los distintos síntomas de alarma. *Aten Primaria* 2003; 31:239-247.
9. Martín-Rabadán, M. No informamos a los pacientes con cardiopatía isquémica sobre 'cómo actuar' al reaparecer el dolor torácico. *GCS* 2003; 5(4):143.
10. McCloskey, DJ; Bulechek, TG;, editoras. Clasificación de intervenciones en enfermería (NIC). 4ª ed. Madrid: Mosby; 2005.
11. Moorhead, S; Jhonson, M; Maas, M; editoras. Clasificación de resultados de enfermería (NOC). 3ª ed. Madrid: Mosby; 2005.
12. NANDA. Nanda Diagnósticos enfermeros: definiciones y clasificación 2005-2006. Madrid: Elsevier; 2007.
13. Nolan, J; Greenwood, J; Mackintosh, A. Atención Urgente y primeros cuidados al paciente con infarto agudo de miocardio. *Salud Rural*,1999; 16:69-72.
14. Portuondo Maseda, MT; Marugán Torres, P; Cabrero Fernández, F; Morales Durán, M; Maroto Montero, JM; Muriel, A. Sobrepeso y deshabitación tabáquica. *Rev Enferm Cardiol* 2006; 13:41-43.
15. Silva Paiva , G da; Oliveira Lopes, MV. Respuestas humanas identificadas en pacientes con infarto agudo del miocardio ingresados en una unidad de terapia intensiva. *Rev Enferm Cardiol* 2005; 12:22-27.